-
1
-
-
0009655168
-
Characteristics of human cancer
-
Ruddon RW(Ed): (4th Edn). Oxford University Press, New York
-
Ruddon RW. Characteristics of human cancer. In: Ruddon RW(Ed): Cancer Biology (4th Edn). Oxford University Press, New York, 2007, pp 3-61.
-
(2007)
Cancer Biology
, pp. 3-61
-
-
Ruddon, R.W.1
-
3
-
-
77953143235
-
Targeted Cancer Therapies
-
Aggarwal S. Targeted Cancer Therapies. Nature Rev, Drug Discov 2010; 9: 427-428.
-
(2010)
Nature Rev, Drug Discov
, vol.9
, pp. 427-428
-
-
Aggarwal, S.1
-
4
-
-
59649129538
-
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-Glycoprotein (ABCB1) and ABCG2
-
Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-Glycoprotein (ABCB1) and ABCG2. Drug Metabol Dispos 2008; 37: 359-365.
-
(2008)
Drug Metabol Dispos
, vol.37
, pp. 359-365
-
-
Shukla, S.1
Robey, R.W.2
Bates, S.E.3
Ambudkar, S.V.4
-
5
-
-
65249087328
-
A population pharmacokinetic meta-analysis of Sunitinib Malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
-
Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of Sunitinib Malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15: 2497-2506.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2497-2506
-
-
Houk, B.E.1
Bello, C.L.2
Kang, D.3
Amantea, M.4
-
6
-
-
33947416658
-
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
-
Roskoski R Jr. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007; 356: 323-328.
-
(2007)
Biochem Biophys Res Commun
, vol.356
, pp. 323-328
-
-
Roskoski Jr., R.1
-
7
-
-
62549157391
-
Induction of apoptosis and cell proliferation inhibition by paclitaxel in FM3A cell cultures
-
Ilgar NN, Arican Ozcan G. Induction of apoptosis and cell proliferation inhibition by paclitaxel in FM3A cell cultures. Afr J Biotechnol 2008; 8: 547-555.
-
(2008)
Afr J Biotechnol
, vol.8
, pp. 547-555
-
-
Ilgar, N.N.1
Arican Ozcan, G.2
-
8
-
-
0017088883
-
Apparent anomalies in nuclear Feulgen-DNA contents
-
Bedi KS, Goldstein DJ. Apparent anomalies in nuclear Feulgen-DNA contents. J Cell Biol 1976; 71: 68-88.
-
(1976)
J Cell Biol
, vol.71
, pp. 68-88
-
-
Bedi, K.S.1
Goldstein, D.J.2
-
9
-
-
0019307591
-
Mechanisms of the Feulgen acid hydrolysis
-
Kjellstrand P. Mechanisms of the Feulgen acid hydrolysis. J Microscopy 1980; 119: 391-396. (Pubitemid 10010604)
-
(1980)
Journal of Microscopy
, vol.119
, Issue.3
, pp. 391-396
-
-
Kjellstrand, P.1
-
10
-
-
33645364706
-
Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)
-
abstr
-
Miller KD, Burstein HJ, Elias AD et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol 2005; 23 (Suppl): 563 (abstr).
-
(2005)
J Clin Oncol
, vol.23
, Issue.SUPPL.
, pp. 563
-
-
Miller, K.D.1
Burstein, H.J.2
Elias, A.D.3
-
11
-
-
33845297206
-
Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial
-
abstr
-
Socinski MA, Novello S, Sanchez JM et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. J Clin Oncol 2006; 24 (Suppl): 7001 (abstr).
-
(2006)
J Clin Oncol
, vol.24
, Issue.SUPPL.
, pp. 7001
-
-
Socinski, M.A.1
Novello, S.2
Sanchez, J.M.3
-
12
-
-
28044447317
-
A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)
-
abstr
-
Kulke M, Lenz HJ, Meropol NJ et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol 2005; 23 (Suppl): 4008 (abstr).
-
(2005)
J Clin Oncol
, vol.23
, Issue.SUPPL.
, pp. 4008
-
-
Kulke, M.1
Lenz, H.J.2
Meropol, N.J.3
-
13
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337. (Pubitemid 36109749)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.1 I
, pp. 327-337
-
-
Mendel, D.B.1
Douglas, L.A.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
Schreck, R.E.7
Abrams, T.J.8
Ngai, T.J.9
Lee, L.B.10
Murray, L.J.11
Carver, J.12
Chan, E.13
Moss, K.G.14
Haznedar, J.O.15
Sukbuntherng, J.16
Blake, R.A.17
Sun, L.18
Tang, C.19
Miller, T.20
Shirazian, S.21
McMahon, G.22
Cherrington, J.M.23
more..
-
14
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
15
-
-
33749544080
-
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/Papillary thyroid cancer kinases
-
Kim WD, Jo SY, Jung SH et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/Papillary thyroid cancer kinases. J Clin Endocrinol Metabol 2006; 91: 4070-4076.
-
(2006)
J Clin Endocrinol Metabol
, vol.91
, pp. 4070-4076
-
-
Kim, W.D.1
Jo, S.Y.2
Jung, S.H.3
-
16
-
-
38449097166
-
Antiangiogenic and antiinvasive effects of sunitinib on experimental human glioblastoma
-
De Boüard S, Herlin P, Christensen JG et al. Antiangiogenic and antiinvasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007; 9: 412-423.
-
(2007)
Neuro Oncol
, vol.9
, pp. 412-423
-
-
De Boüard, S.1
Herlin, P.2
Christensen, J.G.3
-
17
-
-
2442669093
-
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "Standard of care" therapeutic agents for the treatment of breast cancer
-
Abrams TJ, Murray LJ, Pesenti E et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "Standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2: 1011-1021.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 1011-1021
-
-
Abrams, T.J.1
Murray, L.J.2
Pesenti, E.3
-
18
-
-
84879007189
-
Correlation of receptor tyrosine kinase (RTK) activity and apoptosis with response to sunitinib treatment in patients with gastrointestinal stromal tumor (GIST)
-
Davis DW, Heymach JV, Desai J et al. Correlation of receptor tyrosine kinase (RTK) activity and apoptosis with response to sunitinib treatment in patients with gastrointestinal stromal tumor (GIST). 18th EORTC-NCI-AACR Symposium Presentations, 2006, Prague, Czech Republic.
-
18th EORTC-NCI-AACR Symposium Presentations, 2006, Prague, Czech Republic
-
-
Davis, D.W.1
Heymach, J.V.2
Desai, J.3
-
19
-
-
0038204144
-
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
DOI 10.1182/blood-2002-07-2307
-
O'Farell A, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605. (Pubitemid 36857948)
-
(2003)
Blood
, vol.101
, Issue.9
, pp. 3597-3605
-
-
O'Farrell, A.-M.1
Abrams, T.J.2
Yuen, H.A.3
Ngai, T.J.4
Louie, S.G.5
Yee, K.W.H.6
Wong, L.M.7
Hong, W.8
Lee, L.B.9
Town, A.10
Smolich, B.D.11
Manning, W.C.12
Murray, L.J.13
Heinrich, M.C.14
Cherrington, J.M.15
-
20
-
-
77956047415
-
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines
-
Giannopoulou E, Dimitropoulos K, Argyriou AA, Koutras KA, Dimitrakopoulos F, Kalofonos PH. An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. Invest New Drug 2010; 28: 554-560.
-
(2010)
Invest New Drug
, vol.28
, pp. 554-560
-
-
Giannopoulou, E.1
Dimitropoulos, K.2
Argyriou, A.A.3
Koutras, K.A.4
Dimitrakopoulos, F.5
Kalofonos, P.H.6
-
22
-
-
9144274970
-
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
-
DOI 10.1023/B:CLIN.0000006873.65590.68
-
Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exper Metastasis 2003; 20: 757-766. (Pubitemid 38019277)
-
(2003)
Clinical and Experimental Metastasis
, vol.20
, Issue.8
, pp. 757-766
-
-
Murray, L.J.1
Abrams, T.J.2
Long, K.R.3
Ngai, T.J.4
Olson, L.M.5
Hong, W.6
Keast, P.K.7
Brassard, J.A.8
O'Farrell, A.M.9
Cherrington, J.M.10
Pryer, N.K.11
-
23
-
-
67649354223
-
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
-
Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009; 27: 391-399.
-
(2009)
Urol Oncol
, vol.27
, pp. 391-399
-
-
Sonpavde, G.1
Jian, W.2
Liu, H.3
Wu, M.F.4
Shen, S.S.5
Lerner, S.P.6
-
25
-
-
12944329959
-
Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity
-
DOI 10.1073/pnas.090013497
-
Gisselsson D, Pettersson L, Hoglund M et al. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneiry. Proc Natl Acad Sci USA 2000; 97: 5357-5362. (Pubitemid 30313723)
-
(2000)
Proceedings of the National Academy of Sciences of the United States of America
, vol.97
, Issue.10
, pp. 5357-5362
-
-
Gisselsson, D.1
Pettersson, L.2
Hoglund, M.3
Heidenblad, M.4
Gorunova, L.5
Wiegant, J.6
Mertens, F.7
Dal, C.P.8
Mitelman, F.9
Mandahl, N.10
-
26
-
-
0000980730
-
The fusion of broken ends of chromosomes following nuclear fusion
-
McClintock B. The fusion of broken ends of chromosomes following nuclear fusion. Proc Natl Acad Sci USA 1942; 28: 458-463.
-
(1942)
Proc Natl Acad Sci USA
, vol.28
, pp. 458-463
-
-
McClintock, B.1
-
27
-
-
0031004175
-
Genetic instability in colorectal cancers
-
DOI 10.1038/386623a0
-
Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-627. (Pubitemid 27175430)
-
(1997)
Nature
, vol.386
, Issue.6625
, pp. 623-627
-
-
Lengauer, C.1
Kinzler, K.W.2
Vogelstein, B.3
-
28
-
-
0037188898
-
Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations
-
DOI 10.1016/S0092-8674(02)00770-5
-
Zhu C, Mills KD, Ferguson DO et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 2002; 109: 811-821. (Pubitemid 34785997)
-
(2002)
Cell
, vol.109
, Issue.7
, pp. 811-821
-
-
Zhu, C.1
Mills, K.D.2
Ferguson, D.O.3
Lee, C.4
Manis, J.5
Fleming, J.6
Gao, Y.7
Morton, C.C.8
Alt, F.W.9
-
29
-
-
0034978564
-
Telomere dysfunction and evolution of intestinal carcinoma in mice and humans
-
DOI 10.1038/88871
-
Rudolph KL, Millard M, Bosenberg MW, Depinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001; 28: 155-159. (Pubitemid 32538061)
-
(2001)
Nature Genetics
, vol.28
, Issue.2
, pp. 155-159
-
-
Rudolph, K.L.1
Millard, M.2
Bosenberg, M.W.3
DePinho, R.A.4
-
30
-
-
0034632717
-
Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice
-
DOI 10.1038/35020592
-
Artandi SE, Chang S, Lee SL et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-645. (Pubitemid 30641052)
-
(2000)
Nature
, vol.406
, Issue.6796
, pp. 641-645
-
-
Artandl, S.E.1
Chang, S.2
Lee, S.-L.3
Alson, S.4
Gottlieb, G.J.5
Chin, L.6
DePinho, R.A.7
|